semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Type 2 Diabetes Mellitus Obesity Diagnosis of type 2 diabetes Age 18 years or older Overweight or obese (BMI >25 kg/m2) HbA1c level 6.5<11.5% Systolic blood pressure (SBP) <160 mmHg, diastolic blood pressure (DBP) <100 mmHg Willing to lose 5-7% of body weight Willing to increase activity to at least 175 minutes/week Willing to commit to random assignment to either attend and participate in the lifestyle change program in person or on the telephone or be referred to Nutrition Services for medical nutrition therapy Stable health, with no severe comorbidities that might interfere with their ability to participate in a group intervention that includes increasing activity or decreasing calories, such as severe psychiatric illness or significant heart disease Ability to understand and communicate effectively in English or Spanish  Weight greater than 350 pounds Pregnant or planning pregnancy in the next year Currently seeing a dietitian (regular scheduled follow up appointments) or participating in a weight loss program and unwilling to stop Weight change of more than 3% of weight in the previous month Currently enrolled in another diabetes intervention study Lack of availability of telephone
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 19.0-50.0,  Overweight and Obesity BMI of 25-35 men and pre-menopausal, non-pregnant or lactating women weight stability (±3%) for at least 1 month no diagnosis of gastrointestinal disorders or history of gastrointestinal surgical interventions no history of diabetes mellitus  vegetarian or vegan smoking alcohol intake greater than 7 drinks per week vigorous exercise more than 3 hours per week uses supplements (including prebiotics and probiotics) antibiotic treatment in the last 3 months allergy or intolerance to treatment fibers (wheat or acacia gum) use of anti-hypertensive, lipid-lowering, anti-diabetic, anti-inflammatory, or laxative medications
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Diabetes Mellitus, Type 2 Patients will be recruited from the University of California Irvine Federally Qualified Health Center family medicine clinic sites in Santa Ana and Anaheim with the following 1. age 18 and older; 2. have poorly controlled type 2 diabetes (as indicated by HbA1c>7.5%, LDL cholesterol >100 mg/dl or systolic blood pressure > 140), 3. be of Hispanic ethnicity, 4. speak English or Spanish. These data are available to the research team in an automated report emailed to the lead researcher every week in his role as coordinator of the routine care Coaching program. This report includes a list of upcoming appointments for patients who meet these criteria
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 14.0-30.0,  Diabetes Mellitus, Type 1 Age of 14 to 30 years 2. Subjects must be otherwise healthy except for T1DM, and treated for hypothyroidism if present 3. Menstruating women must have negative pregnancy test. 4. Hemoglobin (Hb) more than 12 g/dl  Having any other chronic condition except hypothyroidism stable on medications 2. On chronic medications that may affect glucose excursions 3. Hemoglobin less than 12 g/dl 4. Positive pregnancy test (based on Urine) 5. Pregnant or lactating mothers Known allergy to Januvia-
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Dyspnea Invasive mechanical ventilation in the ICU for > 24 hours Remaining stay in the ICU estimated > 24 hours  RASS <-2 or >+2 Delirium (defined according to CAM-ICU) Severe cognitive impairment or severe psychiatric disease Patient who does not understand French Severe depthless Age <18 years
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Obesity Participants will be screened for based on Age > 21 BMI > 30 kg/m2 No reported unstable chronic disease Participants will not be enrolled in the intervention until they complete the physical assessment component of the baseline visit that includes blood pressure, lipids, and HbA1c Individuals who do not meet the established medical guidelines and regulations of the FMCSA will be excluded. Those individuals will be advised to follow-up for care with their personal physicians, and/or will be referred to a primary care clinic. of women Women will be included as they are represented in this population, although, the investigators expect, at rates that are less than the overall population. This is a convenience sample, thus there will not be attempts to over or under represent genders. The individualization of the interventions increases the likelihood of success of the intervention with both men and women. of minorities The investigators will minorities when possible. This is a convenience sample, so there will not be attempts to either over or under represent any racial or ethnic group. of Children Commercial truck drivers must be 21 to drive interstate routes. Therefore, children, including those 18-20 years old, will not be included
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hypobetalipoproteinemia For index cases without family screening: o Patient with HBL: fasting LDL-C ≤ 50 mg/dl For familial affected cases Relative with HBL: fasting LDL-C ≤ 80 mg/dl and/or Apo B ≤ 50 mg/dl and at least one related family case suffering from HBL. All subjects, including familial non-affected cases, must give written consent (dated and signed) to participate at the constitution of biobank (including DNA samples and urine samples)  Use of lipid-lowering drugs (statins, fibrates, ezetimibe, bile-acid sequestering resin) or nutraceuticals known to affect lipids (red yeast rice, margarine and dairy with plant sterol) Patient screened within an extreme metabolic disturbance (emergency situations, sepsis, hospitalization in intensive care unit) Patients with hyperthyroidism, severe liver failure, end stage chronic kidney disease, serious pancreatic failure, anemia related to thalassemia or sickle cell disease, strict vegan diet or malnutrition Refusal of the patient or his legal representative to participate in the study"
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Fatigue Patients seen in the outpatient palliative care clinic or inpatients seen by the palliative care consult team or the fatigue clinic. 2. Presence of fatigue on a numerical scale during the last 24 hours of more or equal to 4 on a 0 to 10 scale on which 0 equals no fatigue and 10 worst possible fatigue. 3. Patient should describe fatigue as being present for a minimum of four days. 4. If patients are on opioids for the treatment of cancer pain, they must have had no dose changes (>25%) for at least 48 hours prior to study entry. Change in opioid dose after study entry is allowed. 5. Presence of relatively intact cognition defined by normal Mini Mental State Questionnaire according to age and education level. A score of 24 or above is usually considered normal. 6. Signed written informed consent. 7. Patient must be 18 years or older.The questionnaires used in this study have been validated only in the adult population. 8. Patient willing to keep a daily fatigue diary, engage in daily telephone follow up with a nurse and after 7 days of treatment either return for a follow up visit or this can be done over the telephone. 9. Hemoglobin of >/=10 g/dl within 2 weeks of enrollment. If the patient has not had blood drawn for a hemoglobin level in the past two weeks, one will be done to determine the eligibility  Major contraindication to methylphenidate i.e. hypersensitivity 2. Currently on methylphenidate or has been on methylphenidate within the last 10 days. 3. Inability to complete the baseline assessment forms or to understand the recommendations for participation in the study. 4. Pregnant or lactating women. Childbearing age women are not on birth control. 5. Patients taking MAO inhibitors, tricyclic antidepressants, clonidine, psychostimulants, concurrent steroids or other medications specifically for fatigue 6. Patients with glaucoma, history of marked anxiety disorder, or history of substance abuse. 7. CAGE questionnaire score is 2 or above on a 0 to 4 scale. 8. Patients with history of seizures or uncontrolled CNS disease, significant hepatic or renal dysfunction
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Diabetes Mellitus, Type 1 DM1 Use of insulin pump Disease duration ≥ 3 years  Presence of chronic complications of DM (including cardiovascular autonomic neuropathy) BMI ≥ 30 kg/m2 Presence of chronic diseases other than DM1 Diseases that interfere with GE Medications that interfere with blood glucose homeostasis (except insulin) and GE
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Obesity Heart Failure patient schedulled for coronary artery bypass graft surgery or aortic valve replacement surgery with extracorporeal circulation must be over 18 years of age must be able to read and understand the consent form in French must be in sinus rhythm at time  medical history of type 1 diabetes medical history of sustained atrial arrhythmia pregnancy class III anti-arhythmic drug
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hyperlipidemias Cardiovascular Diseases Men and women age> 18 years who are initiated on statin therapy in the clinical setting  History of rhabdomyolysis 2. History of prior allergic reaction to statins 3. History of liver failure 4. Contraindications to antecubital phlebotomy or finger stick (including those with bilateral dialysis AV fistulae)
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 30.0-70.0,  Type 2 Diabetes BMI: 26-34 kg/m2 HbA1c > 7 % T2D since < 10 yrs  Only non treated or treated with oral antidiabetic drugs Those treated with insulin or GLP-1 analogs will be excluded  Type 1 diabetes Serum creatinine level > 1.5 mg/dl Pulmonary disease, psychiatric, immunological, neoplastic diseases or severe diabetic complications,such as cardiovascular disease, cerebrovascular disease, proliferative diabetic retinopathy, gastroparesis or anemia (Hg > 10g/dL) or underwent bariatric surgery Abnormal liver function tests Participating in dietary program or using of weight-loss medications History (within one year) of illicit drug abuse or alcoholism Use of psychotropic or anoretic medication during the month immediately prior to study onset
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 19.0-50.0,  Vitamin D Deficiency A. for Objective 1 (Part One): 1. Adult volunteers, male or female, between 19 and 50 years of age; 2. Body mass index (BMI) ≥20 and ≤30 kg/m2 (normal to overweight); 3. Must be on a stable regime for the past three months, if taking vitamin and mineral/dietary/herbal supplements; and 4. Willing to provide informed consent. B. for Objective 2 (Part Two): 1. Adult volunteers, male or female, between 19 and 50 years of age; 2. Body mass index (BMI) ≥20 and ≤30 kg/m2 (normal to overweight); 3. Must be on a stable regime for the past three months, if taking vitamin and mineral/dietary/herbal supplements; 4. Vitamin D insufficient (serum 25(OH)D concentrations ≥30 and ≤75 nmol/L); 5. Willing to comply with protocol requirements; and 6. Willing to provide informed consent  Take a vitamin D or calcium supplement within the last three months before the start date of the study, or during the study; 2. History of vitamin D deficiency (serum 25(OH)D concentration <30 nmol/L); 3. History of hypocalcaemia; 4. Presence of a clinically diagnosed disease affecting the circulatory, respiratory, immune, skeletal, urinary, muscular, endocrine, digestive, nervous or reproductive system that requires medical treatment; 5. Taking any medication (with the exception of birth control); 6. Daily consumption of more than three servings of dairy products; 7. Undergone significant sun exposure one month before start date of the study; 8. Use or have used a tanning booth one month before start date of the study, or during the study; 9. Plan to travel to a sunny climate during the study; 10. Currently smoking or have smoked within the last six months before start date of the study, or during the study; 11. Have allergies to tea products; 12. Pregnant or lactating; and 13. Consume excessive alcohol (>10 drinks/week for women, >15 drinks/week for men)
Patient description: The patient is a 25-year-old man with type 1 diabetes confirmed with molecular analysis 7 years ago. He presents to the clinic with shortness of breath and fatigue during activities. He claims mild dyspnea after climbing 3 floors, no dyspnea at rest and no angina (New York Heart Association class 2). He is diagnosed with cardiomyopathy that will be treated with ACE inhibitors and Beta blockers. His takes 70/30 Insulin and vitamin D supplements. His past medical history is not significant for any other medical issues. His family history is positive for DM type 1 in his uncle and his grandfather. His lab study is as bellow: FBS: 100 mg/dl HbA1c: 6.5% Cholesterol: 190 mg/dl TG: 140 mg/dl LDL: 125 mg/dl HDL: 40 mg/dl

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Dyspnea Patient in home hospice care with an estimated survival of 3-4 weeks, at risk for dyspnea secondary to lung cancer, COPD, or heart failure Family caregiver in patient's home must speak and read English  Patients with bulbar ALS or quadriplegia